Business Context and Reporting Period
This Form 8-K Current Report was filed by PerkinElmer, Inc. (noted as REVVITY, INC. in metadata) on November 7, 2011. The report details the completion of the acquisition of Caliper Life Sciences, Inc. ("Caliper"), which was consummated on September 7, 2011, pursuant to an Agreement and Plan of Merger.
Key Financial Metrics
- Total Net Purchase Price: Approximately $600 million.
- Merger Consideration per Share: $10.50 in cash per share of Caliper common stock, without interest and less applicable withholding taxes.
- Stock Options and RSUs: Outstanding options were cancelled for cash equal to the excess of the merger consideration over the exercise price; unvested restricted stock units were cancelled for cash equal to the merger consideration multiplied by the number of shares subject to the unit.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes
The primary material change is the acquisition of 100% of the outstanding voting securities of Caliper Life Sciences, Inc., making it a wholly owned subsidiary of PerkinElmer, Inc. This transaction was executed via a merger with PerkinElmer Hopkinton Co., an indirect wholly owned subsidiary of the registrant.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors related to the acquisition beyond the standard legal descriptions of the merger mechanics. The document notes that financial statements of the acquired business and pro forma financial information are not included in this filing but will be submitted via amendment within 71 days if required.
Investor Verification Checklist
- Verify the final closing date of the merger (September 7, 2011) against the press release attached as Exhibit 99.1.
- Confirm the total net purchase price of approximately $600 million in subsequent financial filings.
- Monitor the upcoming amendment to this Form 8-K for the required financial statements of Caliper and pro forma financial information, due within 71 days of the filing date.
- Review the full text of the Agreement and Plan of Merger (Exhibit 2.1) for specific exceptions to the cash conversion of shares.